作者:Karin Worm、Q. Jean Zhou、Christopher T. Saeui、Rosalyn C. Green、Joel A. Cassel、Gabriel J. Stabley、Robert N. DeHaven、Nathalie Conway-James、Christopher J. LaBuda、Michael Koblish、Patrick J. Little、Roland E. Dolle
DOI:10.1016/j.bmcl.2008.04.006
日期:2008.5
Sulfamoyl benzamides were identified as a novel series of cannabinoid receptor ligands. Starting from a screening hit 8 that had modest affinity for the cannabinoid CB(2) receptor, a parallel synthesis approach and initial SAR are described, leading to compound 27 with 120-fold functional selectivity for the CB(2) receptor. This compound produced robust antiallodynic activity in rodent models of postoperative
氨磺酰基苯甲酰胺被确定为一系列新的大麻素受体配体。从对大麻素CB(2)受体具有适度亲和力的筛选命中8开始,描述了一种平行合成方法和初始SAR,从而导致化合物27对CB(2)受体的功能选择性为120倍。该化合物在术后疼痛和神经性疼痛的啮齿动物模型中产生了强大的抗痛觉过敏活性,而没有传统的大麻素副作用。